Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Financial Officer | April 30, 2019 | June 07, 2019 |
| Jiya Acquisition Corp.JYAC · Entity 123583 | Director | November 18, 2020 | November 19, 2020 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director | May 29, 2025 | June 02, 2025 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | June 08, 2026 | June 10, 2026 |
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director | May 21, 2026 | May 26, 2026 |
| vTv Therapeutics Inc.VTVT · Entity 6614 | Director | June 26, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date April 30, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,686 |
Reported balance
After 2019-04-30 transaction · row 1
1 source rowRow 1 · 2019-04-30 · Grant · Acquired 176 · Balance 47,686 F1: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan.
Jiya Acquisition Corp.
Report date November 18, 2020 · Filed November 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-11-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date. F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date.
F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination.
Kyverna Therapeutics, Inc.
Report date May 29, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,634 |
Reported balance
After 2025-05-29 transaction · row 1
1 source rowRow 1 · 2025-05-29 · Grant · Acquired 16,634 · Balance 16,634 F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2035-05-29 | Direct | 65,351 |
Reported balance
After 2025-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-29 · Grant · Acquired 65,351 · Balance 65,351 F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Maze Therapeutics, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07 | Direct | 18,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000 F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
SPRUCE BIOSCIENCES, INC.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.70 · Expires 2036-05-20 | Direct | 1,700 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,700 · Balance 1,700 F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
vTv Therapeutics Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.08 · Expires 2036-06-26 | Direct | 16,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 6,000 · Balance 16,000 F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cascadian Therapeutics, Inc.
Report date March 09, 2018 · Filed March 13, 2018
Section 16 reporting ended · disclosed 2018-03-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 1
1 source rowRow 1 · 2018-03-09 · Other · Disposed 21,006 · Balance 0 F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-09 · Disposition to issuer · Disposed 13,927 · Balance 0 F2: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F3: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date. F4: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
F2: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
F3: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date.
F4: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.
MYRIAD GENETICS INC
Report date June 06, 2024 · Filed June 07, 2024
Section 16 reporting ended · disclosed 2024-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,917 |
Reported balance
Holding disclosure · report date 2024-06-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 32,917 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2018 Filed Mar 20, 2018 01:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,815 | $83.57 | $318,819.55 |
DisclosureSEC source: 0001140361-18-014184 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,705 Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerRestricted Stock Units · Derivative | 13,927 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007301 · doc4.xml · derivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,927 shares Expires not disclosed F2 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F2 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F3 · derivative.exercise_date: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date. F4 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | OtherCommon Stock | 21,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007301 · doc4.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 01:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,609 | $79.86 | $128,494.74 |
DisclosureSEC source: 0001140361-18-012370 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,520 Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 01:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011000 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,129 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. Read SEC document |
| February 26, 2018 Filed Apr 27, 2018 01:04 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-019878 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,215 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F4 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of RSUs reported as earned. Read SEC document |
| October 31, 2017 Filed Feb 15, 2018 01:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 162 | $69.78 | $11,303.87 |
DisclosureSEC source: 0001140361-18-008551 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,600 F1 · date: Represents shares acquired by the reporting person on October 31, 2017, pursuant to the issuer's Employee Stock Purchase Plan. F2 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) include 34,078 shares reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) include 57 shares inadvertently excluded in prior reports based on a reconciliation with the Company's records. Read SEC document |
| September 24, 2017 Filed Sep 26, 2017 17:22 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionRestricted Share Unit (RSU) · Derivative | 2,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-054020 · doc4.xml · derivative · entry 3 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: The RSU was 100% vested on September 24, 2017. F3 · derivative.expiration_date: The RSU was 100% vested on September 24, 2017. Read SEC document |
| September 24, 2017 Filed Sep 26, 2017 17:22 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Tax withholdingCommon Stock | 594 | $3.94 | $2,340.36 |
DisclosureSEC source: 0001209191-17-054020 · doc4.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,006 F1 · shares: 594 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on September 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on September 22, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F1 · price: 594 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on September 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on September 22, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Read SEC document |
| September 24, 2017 Filed Sep 26, 2017 17:22 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionCommon Stock | 2,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-054020 · doc4.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2017 Filed Jun 27, 2017 17:41 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionRestricted Share Unit (RSU) · Derivative | 9,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042008 · doc4.xml · derivative · entry 3 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: The RSU was 100% vested on June 24, 2017. F3 · derivative.expiration_date: The RSU was 100% vested on June 24, 2017. Read SEC document |
| June 24, 2017 Filed Jun 27, 2017 17:41 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Tax withholdingCommon Stock | 2,265 | $3.78 | $8,561.70 |
DisclosureSEC source: 0001209191-17-042008 · doc4.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,225 F1 · shares: 2,265 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 23, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F1 · price: 2,265 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 23, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Read SEC document |
| June 24, 2017 Filed Jun 27, 2017 17:41 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionCommon Stock | 9,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042008 · doc4.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 16:42 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionRestricted Share Unit (RSU) · Derivative | 2,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039503 · doc4.xml · derivative · entry 4 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F4 · derivative.exercise_date: The RSU was 100% vested on June 12, 2017. F4 · derivative.expiration_date: The RSU was 100% vested on June 12, 2017. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 16:42 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Tax withholdingCommon Stock | 537 | $3.34 | $1,793.58 |
DisclosureSEC source: 0001209191-17-039503 · doc4.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,432 F1 · shares: 537 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 12, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 12, 2017 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F1 · price: 537 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 12, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 12, 2017 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 16:42 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionCommon Stock | 2,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039503 · doc4.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 16:42 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantRestricted Share Unit (RSU) · Derivative | 13,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039503 · doc4.xml · derivative · entry 3 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,927 Underlying: Common Stock · 13,927 shares Expires not disclosed F2 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: 100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances. F3 · derivative.expiration_date: 100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances. Read SEC document |
| June 02, 2017 Filed Jun 7, 2017 01:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,801 | $90.72 | $163,386.72 |
DisclosureSEC source: 0001140361-17-024250 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,303 Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,722 | $91.50 | $157,563.00 |
DisclosureSEC source: 0001140361-17-021241 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,104 Read SEC document |
| April 28, 2017 Filed May 17, 2017 22:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 155 | $70.30 | $10,897.12 |
DisclosureSEC source: 0001140361-17-021241 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,826 F1 · date: Represents shares acquired by the reporting person pursuant to issuer's Employee Stock Purchase Plan. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 39,480 | $0.00 Strike: $87.42 | $0.00 |
DisclosureSEC source: 0001140361-17-013315 · doc1.xml · derivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,480 Underlying: Common Stock · 39,480 shares Expires 2027-03-21 F2 · derivative.exercise_date: Option grant vests 12/48th on March 22, 2018 and 1/48th on the 22nd day of each month thereafter. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-013315 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,671 F1 · price: Restricted stock units granted on March 22, 2017. Price not applicable. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,989 | $91.96 | $182,908.44 |
DisclosureSEC source: 0001140361-17-012643 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,471 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 16, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,301 | $92.50 | $397,842.50 |
DisclosureSEC source: 0001140361-17-012643 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,460 Read SEC document |
| March 06, 2017 Filed Mar 9, 2017 00:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,303 | $93.32 | $214,915.96 |
DisclosureSEC source: 0001140361-17-011079 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,761 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 16, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 23:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,283 | $93.95 | $214,487.85 |
DisclosureSEC source: 0001140361-17-010935 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,064 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $94.50 | $472,500.00 |
DisclosureSEC source: 0001140361-17-010370 · doc1.xml · nonDerivative · entry 3 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,347 F1 · date: Transaction made pursuant to a 10b5-1 trading plan executed on November 16, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy) Common Stock · Derivative | 30,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001140361-17-010370 · doc1.xml · derivative · entry 4 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,700 Underlying: Common Stock · 30,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction made pursuant to a 10b5-1 trading plan executed on November 16, 2016. F3 · derivative.exercise_date: Original option grant vests 6/48ths on December 4, 2014, and 1/48th on the 4th day of every month thereafter. F4 · balance_after: Reflects the number of stock options that remain outstanding from this specific stock grant following the reported transaction. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 30,000 | $94.00 | $2,820,000.00 |
DisclosureSEC source: 0001140361-17-010370 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,347 F1 · date: Transaction made pursuant to a 10b5-1 trading plan executed on November 16, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 30,000 | $63.10 | $1,893,000.00 |
DisclosureSEC source: 0001140361-17-010370 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction made pursuant to a 10b5-1 trading plan executed on November 16, 2016. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-009697 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,347 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the fiscal year ended December 31, 2016, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2017, 2018 and 2019, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 21:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $90.00 | $450,000.00 |
DisclosureSEC source: 0001140361-17-001375 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,100 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 16, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 19:02 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 20,000 | $90.61 | $1,812,206.00 |
DisclosureSEC source: 0001140361-16-086264 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,100 F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $90.18 to $91.305. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| October 31, 2016 Filed Nov 14, 2016 19:02 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 156 | $68.44 | $10,676.95 |
DisclosureSEC source: 0001140361-16-086264 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,100 F1 · date: Represents shares acquired by the reporting person on October 31, 2016, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| June 06, 2016 Filed Feb 10, 2017 16:42 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionRestricted Share Unit (RSU) · Derivative | 2,723 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009572 · doc5.xml · derivative · entry 3 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F1 · shares: Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock. The number of shares above reflects the reverse stock split. F5 · derivative.exercise_date: The RSU was 100% vested on June 6, 2016. F5 · derivative.expiration_date: The RSU was 100% vested on June 6, 2016. Read SEC document |
| June 06, 2016 Filed Feb 10, 2017 16:42 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Tax withholdingCommon Stock | 681 | $7.38 | $5,025.78 |
DisclosureSEC source: 0001209191-17-009572 · doc5.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,821 F2 · shares: 681 shares (which number reflects post-reverse split shares) of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 6, 2016, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 6, 2016, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F2 · price: 681 shares (which number reflects post-reverse split shares) of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 6, 2016, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 6, 2016, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F3 · price: Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock. The price above reflects the reverse stock split. Read SEC document |
| June 06, 2016 Filed Feb 10, 2017 16:42 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionCommon Stock | 2,723 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009572 · doc5.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock. The number of shares above reflects the reverse stock split. F1 · balance_after: Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock. The number of shares above reflects the reverse stock split. Read SEC document |
| May 27, 2015 Filed Oct 14, 2017 00:43 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 34,078 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001140361-17-038689 · doc1.xml · derivative · entry 3 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,552 Underlying: Common Stock · 34,078 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On May 28, 2015, the reporting person filed a Form 4 which inadvertently failed to report this option exercise. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2015. Read SEC document |
| May 27, 2015 Filed Oct 14, 2017 00:43 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 34,078 | $130.00 | $4,430,140.00 |
DisclosureSEC source: 0001140361-17-038689 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,585 F3 · date: On May 28, 2015, the reporting person filed a Form 4 which inadvertently reported an incorrect transaction date and deemed execution date. This amendment corrects such date. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2015. F4 · price: All shares sold at same price. Read SEC document |
| May 27, 2015 Filed Oct 14, 2017 00:43 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 34,078 | $67.81 | $2,310,829.18 |
DisclosureSEC source: 0001140361-17-038689 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On May 28, 2015, the reporting person filed a Form 4 which inadvertently failed to report this option exercise. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.